Patrick J. Heron

Patrick J. Heron, listed as board member, has filed trades across 8 companies (mainly through SEC (Form 4)), most often in Arcutis Biotherapeutics, Inc., Mirum Pharmaceuticals, Inc. and Iterum Therapeutics plc. In total, 52 filings cover trades dated from 30 May 2018 to 5 June 2026.

Every open-market trade on record is a purchase: 25 purchases worth €46.5M, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 6 share grants and 3 option exercises.

Half of the purchases are above €76k and half below. On 7 out of 23 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 9 June 2026, the filings show a share grant in Arcutis Biotherapeutics, Inc. The last insider purchase was made public on 30 September 2025, 386 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.